BioXcel Therapeutics Appoints Dr. David C. Hanley as Vice President and Head of Global Pharmaceutical Development and Operati...
September 04 2018 - 08:00AM
BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage
biopharmaceutical development company utilizing novel artificial
intelligence to identify the next wave of medicines across
neuroscience and immuno-oncology, today announced the appointment
of Dr. David C. Hanley as Vice President and Head of Global
Pharmaceutical Development and Operations, effectively immediately.
Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI,
commented, “David possesses a wealth of knowledge and expertise in
drug development, clinical and commercial manufacturing, and supply
chain management which will be instrumental in the success of our
clinical programs, BXCL501 and BXCL701, as well as setting the
stage for our commercial operations. David represents another
important addition to our world-class leadership team. I am
confident that his contributions will be important for future
milestones related to our current development candidates and our
emerging pipeline in neuroscience and immuno-oncology.”
“I am excited to join BTI and to lead the pharmaceutical
development and operational efforts for its impressive clinical and
preclinical pipeline,” commented Dr. Hanley. “I look forward to
identifying and executing on the product development opportunities
through all stages to maximize the potential of our programs and to
have a positive impact on the lives of patients in need.”
Dr. Hanley has 17 years of experience in Chemistry,
Manufacturing and Controls (CMC) and Technical Operations functions
and cross-functional development teams in the U.S. and Europe. Most
recently, Dr. Hanley was the Vice President of Pharmaceutical
Sciences at Radius Health Inc. (NASDAQ: RDUS), subsequent to
serving as Executive Director of Technical Operations, where he was
responsible for technical development, CMC Regulatory approval and
a successful commercial launch in the US. Prior to joining Radius
Health, Dr. Hanley served in various roles of increasing
responsibility, including Senior Director, Global Pharmaceutical
Development at The Medicines Company and Global Program Management
roles at each of The Medicines Company, Medarex Inc. and Schering
AG. Dr. Hanley began his career in CMC development at Berlex
Laboratories / Schering A.G. in the US and in Europe.
Dr. Hanley received his bachelor’s degree in chemistry from
Virginia Commonwealth University. He earned a doctorate in physical
and analytical chemistry from University of Utah. He has authored
multiple peer-reviewed publications, conference presentations, and
patents.
About BioXcel Therapeutics, Inc.:BioXcel
Therapeutics, Inc. is a clinical stage biopharmaceutical company
focused on drug development that utilizes novel artificial
intelligence approaches to identify the next wave of medicines
across neuroscience and immuno-oncology. The Company's drug
re-innovation approach leverages existing approved drugs and/or
clinically validated product candidates together with big data and
proprietary machine learning algorithms to identify new therapeutic
indices. The Company's two most advanced clinical development
programs are BXCL501, a sublingual thin film formulation designed
for acute treatment of agitation resulting from neurological and
psychiatric disorders, and BXCL701, an immuno-oncology agent
designed for treatment of a rare form of prostate cancer and for
treatment of pancreatic cancer. For more information, please visit
www.bioxceltherapeutics.com.
Forward-Looking StatementsThis press release
includes “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of
BXCL701, the commencement of clinical trials, the availability of
data from clinical trials and other information that is not
historical information. When used herein, words such as
“anticipate”, “being”, “will”, “plan”, “may”, “continue”, and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
BioXcel’s current expectations and various assumptions. BioXcel
believes there is a reasonable basis for its expectations and
beliefs, but they are inherently uncertain. BioXcel may not realize
its expectations, and its beliefs may not prove correct. Actual
results could differ materially from those described or implied by
such forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption “Risk Factors” in BioXcel’s 10
Q for the Quarter ended June 30, 2018 and BioXcel’s other filings
made with the Securities and Exchange Commission. Consequently,
forward-looking statements should be regarded solely as BioXcel’s
current plans, estimates and beliefs. Investors should not place
undue reliance on forward-looking statements. BioXcel cannot
guarantee future results, events, levels of activity, performance
or achievements. BioXcel does not undertake and specifically
declines any obligation to update, republish, or revise any
forward-looking statements to reflect new information, future
events or circumstances or to reflect the occurrences of
unanticipated events, except as may be required by law.
Contact Information:The Ruth GroupLee Roth/
Janhavi Mohite646-536-7012/
7026
lroth@theruthgroup.com/ jmohite@theruthgroup.com
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Feb 2024 to Mar 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Mar 2023 to Mar 2024